MaaT Pharma (FR:MAAT)
:MAAT
Want to see FR:MAAT full AI Analyst Report?
Total Valuation
MaaT Pharma has a market cap or net worth of €102.78M. The enterprise value is €85.92M.
Market Cap€102.78M
Enterprise Value€85.92M
Share Statistics
MaaT Pharma has 18,824,076 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,824,076
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
MaaT Pharma’s return on equity (ROE) is -17.27 and return on invested capital (ROIC) is -101.22%.
Return on Equity (ROE)-17.27
Return on Assets (ROA)-0.70
Return on Invested Capital (ROIC)-101.22%
Return on Capital Employed (ROCE)-1.24
Revenue Per Employee76.68K
Profits Per Employee-526.46K
Employee Count59
Asset Turnover0.10
Inventory Turnover37.32
Valuation Ratios
The current PE Ratio of MaaT Pharma is ―. MaaT Pharma’s PEG ratio is 0.22.
PE Ratio―
PS Ratio16.94
PB Ratio42.60
Price to Fair Value42.60
Price to FCF-4.64
Price to Operating Cash Flow-5.76
PEG Ratio0.22
Income Statement
In the last 12 months, MaaT Pharma had revenue of 4.52M and earned -31.06M in profits. Earnings per share was -1.95.
Revenue4.52M
Gross Profit1.39M
Operating Income-34.15M
Pretax Income-34.85M
Net Income-31.06M
EBITDA-32.41M
Earnings Per Share (EPS)-1.95
Cash Flow
In the last 12 months, operating cash flow was -15.91M and capital expenditures -609.00K, giving a free cash flow of -16.52M billion.
Operating Cash Flow-15.91M
Free Cash Flow-16.52M
Free Cash Flow per Share-0.88
Dividends & Yields
MaaT Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.28
52-Week Price Change0.69%
50-Day Moving Average6.73
200-Day Moving Average5.20
Relative Strength Index (RSI)37.66
Average Volume (3m)99.82K
Important Dates
MaaT Pharma upcoming earnings date is Sep 30, 2026, Before Open (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateSep 30, 2026
Ex-Dividend Date―
Financial Position
MaaT Pharma as a current ratio of 1.94, with Debt / Equity ratio of 969.43%
Current Ratio1.94
Quick Ratio1.94
Debt to Market Cap0.18
Net Debt to EBITDA0.23
Interest Coverage Ratio-26.91
Taxes
In the past 12 months, MaaT Pharma has paid -3.79M in taxes.
Income Tax-3.79M
Effective Tax Rate0.11
Enterprise Valuation
MaaT Pharma EV to EBITDA ratio is -2.14, with an EV/FCF ratio of -4.19.
EV to Sales15.30
EV to EBITDA-2.14
EV to Free Cash Flow-4.19
EV to Operating Cash Flow-4.35
Balance Sheet
MaaT Pharma has €24.87M in cash and marketable securities with €17.44M in debt, giving a net cash position of €7.43M billion.
Cash & Marketable Securities€24.87M
Total Debt€17.44M
Net Cash€7.43M
Net Cash Per Share€0.39
Tangible Book Value Per Share>-€0.01
Margins
Gross margin is 49.89%, with operating margin of -754.86%, and net profit margin of -686.58%.
Gross Margin49.89%
Operating Margin-754.86%
Pretax Margin-770.45%
Net Profit Margin-686.58%
EBITDA Margin-716.51%
EBIT Margin-754.86%
Analyst Forecast
The average price target for MaaT Pharma is €18.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€18.00
Price Target Upside226.68% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast40.67%
EPS Growth Forecast11.49%